SINGAPORE, Aug. 28, 2025 — EUDA Health Holdings Limited (NASDAQ: EUDA) (“EUDA” or the “Company”), a leading non-invasive healthcare provider based in Singapore with operations in Singapore, Malaysia, and China, announced today the signing of a Letter of Intent (the “LOI”) for the potential acquisition of Chemokine Pte Ltd (“Chemokine”).

EUDA intends to conduct due diligence on Chemokine, pending confidentiality agreements. Chemokine has consented to an exclusivity period of at least 120 days, during which it will refrain from engaging in discussions with any other entity regarding a transaction comparable to this prospective acquisition.

Chemokine is a biotech company located in Singapore, specializing in molecular supplements and gene-modulating formulations. This includes, among other products, a next-generation immune health supplement for which it previously granted EUDA exclusive worldwide distribution rights, to be marketed by EUDA and its subsidiaries under the brand name Euda Helixé.

Chemokine was established by its primary shareholder, Professor Kah Meng Lim, a molecular medicine researcher with extensive scientific expertise. Prof. Lim obtained his Ph.D. in Molecular Medicine from the National University of Singapore and dedicated several years to research positions within Singapore’s national R&D agency, A*STAR. His contributions connect academic science with consumer health innovation, earning him wide recognition for transforming intricate biological discoveries into practical health solutions.

What Makes Euda Helixé Different

Euda Helixé is formulated to enhance energy, immune resilience, and cellular health, utilizing a blend that extends beyond conventional supplements. It integrates molecular deer placenta, marine collagen, and bioactive antioxidants such as astaxanthin, L-glutathione, grape seed oil, sea-buckthorn oil, and refined avocado oil. These components are delivered via a capsule system designed to safeguard and ensure maximal absorption of the ingredients.

Euda Helixé operates based on a gene activation model, engineered to modulate gene expression by activating advantageous genes and deactivating detrimental ones.

About EUDA Health Holdings Limited

EUDA Health Holdings Limited (NASDAQ: EUDA) stands as a prominent non-invasive healthcare provider in Asia, headquartered in Singapore and concentrating its efforts on Singapore, Malaysia, and China. The Company endeavors to emerge as a market frontrunner in non-invasive and preventive healthcare, with a key strategic emphasis on the rapidly expanding longevity sector. Its objective is to cater to the changing healthcare demands of over 1.8 billion individuals throughout the region, which is undergoing substantial demographic changes with over 30% of its populace aging quickly. By providing inventive, readily available, and scientifically supported health solutions, EUDA is strategically positioned to spearhead the evolution of regional healthcare from reactive medical interventions toward proactive, longevity-centric care. Additionally, EUDA operates a property management business based in Singapore.

Forward Looking Statements

This document potentially includes forward-looking statements concerning risks and uncertainties. Such statements typically employ forward-looking terminology, including terms like “estimates,” “projected,” “expects,” “envisions,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “should,” “future,” “propose,” and their variations or similar expressions (or their negative forms). These forward-looking statements do not assure future performance, conditions, or results, and encompass numerous known and unknown risks, uncertainties, assumptions, and other critical factors, many of which are beyond EUDA’s influence. These factors could cause actual results or outcomes to diverge significantly from those presented in the forward-looking statements. Readers are cautioned not to place undue reliance on forward-looking statements, as they are pertinent only to the date of this document’s publication. These forward-looking statements are founded on data from EUDA and Chemokine, alongside other sources deemed credible. The Company disclaims any obligation to update or amend any forward-looking statements, whether due to new information, future occurrences, or otherwise, except where mandated by law.

Contact:

Christensen Advisory

Linda Bergkamp

Phone: +1-480-614-3004

E-mail: